Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity

2004

Abstract Objectives We sought to assess the age-specific prevalence of oral lichen planus (OLP) in Mediterranean patients with chronic hepatitis C virus (HCV) and to evaluate the features of OLP in relation to sex, smoking, HCV genotype, HIV-1 coinfection, and antiviral treatments. Methods In all, 178 anti-HCV-positive adults (60 women and 118 men; age range 20-66 years) recruited from two cohorts (104 HIV-negative patients and 74 patients with HIV coinfection) underwent oral examination. Results Overall prevalence of OLP was 2.8% (5 of 178) (male/female ratio 0.2; odds ratio=0.119; 95% confidence interval=0.013-1.106), only among HIV-negative participants, always in the reticular pattern, …

Liver CirrhosisMaleHepacivirusHIV Infectionsclinical-featureComorbidityHepacivirusmedicine.disease_causeCohort Studieschemistry.chemical_compoundPrevalenceMedicineExtrahepatic manifestationbiologySmokingvirus diseasesMiddle AgedHepatitis CCoinfectionFemalegeneral-populationmedicine.drugAdultmedicine.medical_specialtyGenotypeHepatitis C virushuman-immunodeficiency-viruDermatologyHCV hyperendemic areaAntiviral AgentsFlaviviridaeAge Distributionstomatognathic systemInternal medicineHumansInterferon alfaAgedbusiness.industryRibavirinChronic active hepatitiOdds ratiomedicine.diseasebiology.organism_classificationstomatognathic diseaseschemistrypositive patientsImmunologynegative patientliver-diseaseOral lichen planusinterferon therapybusinessLichen Planus Oral
researchProduct

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver tran…

2017

Sebastian Bernuth,1 Daniel Grimm,1 Johanna Vollmar,1 Felix Darstein,1 Jens Mittler,2 Michael Heise,2 Maria Hoppe-Lotichius,2 Peter R Galle,1 Hauke Lang,2 Tim Zimmermann1 1First Department of Internal Medicine, Transplant Hepatology, 2General-, Abdominal- and Transplant- Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany Background: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT.Methods: We retrospe…

Liver CirrhosisMaleHepacivirusmedicine.medical_treatmentPharmaceutical ScienceHepacivirusLiver transplantationGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRecurrenceDrug DiscoveryMedicine030212 general & internal medicineOriginal Researchbiologyliver transplantationvirus diseasesMiddle AgedTreatment OutcomeCohortHCV030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseCohort studymedicine.medical_specialtySVRAntiviral Agentsreinfection03 medical and health sciencesInternal medicineHumansSurvival analysisAgedRetrospective StudiesDAAPharmacologyDrug Design Development and Therapybusiness.industryRibavirinRetrospective cohort studyHepatitis C Chronicbiology.organism_classificationVirologySurvival Analysisdigestive system diseasesDiscontinuationchemistrybusinessDrug design, development and therapy
researchProduct

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients

2013

BACKGROUND: Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection or with HCV mono-infection. AIM: The study aims were to assess steatosis prevalence and its risk factors in both HCV groups. We also evaluated whether steatosis was linked with advanced fibrosis. Sixty-eight HIV/HCV co-infected and 69 HCV mono-infected patients were consecutively enrolled. They underwent liver ultrasonography and transient elastography. Bright liver echo-pattern was used to diagnose steatosis; advanced fibrosis was defined as liver stiffness ≥ 9.5 kPa…

Liver CirrhosisMaleHepatic steatosisTransient elastographySpecialties of internal medicineHIV Infectionsmedicine.disease_causeGastroenterologyRisk FactorsFibrosisPrevalenceFIB–4CoinfectionGeneral MedicineHepatitis CMiddle AgedItalyRC581-951Area Under CurveFIB-4Elasticity Imaging TechniquesFemaleLipodystrophyAdultmedicine.medical_specialtyHepatitis C virusLiver fibrosisHepatic steatosiWhite PeopleHIV/HCV co-infectionPredictive Value of TestsInternal medicinemedicineHumansChi-Square DistributionHepatologybusiness.industryLiver fibrosiHepatitis C Chronicmedicine.diseaseImpaired fasting glucoseFatty LiverLogistic ModelsROC CurveMultivariate AnalysisSteatosisMetabolic syndromeTransient elastographybusinessBiomarkersAnnals of Hepatology
researchProduct

Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

2017

Background & Aims Assessment of long-term outcome is required in hepatitis C virus (HCV)-infected patients with cirrhosis, who have been successfully treated for Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC). However, problems arise due to the lack of models accounting for early changes during follow-up. The aim of this study was to estimate the impact of early events (HCC recurrence or hepatic decompensation within 12Â months of complete radiological response) on 5-year overall survival (OS) in a large cohort of patients with HCV and cirrhosis, successfully treated HCC. Methods A total of 328 consecutive Caucasian patients with HCV-related cirrhosis and BC…

Liver CirrhosisMaleHepatocellular Carcinoma Liver Cirrhosis hepatitis C virus Survival direct-acting antiviral agentsSurvival rateCirrhosisAntiviral agentGastroenterologyLiver cirrhosi0302 clinical medicineRecurrenceHepatic decompensation; Hepatitis C Virus (HCV); Hepatocellular carcinoma (HCC); Prognosis; Recurrences; Sustained virological response (SVR); overall survival (OS)Overall survivalLiver NeoplasmsHepatitis Coverall survival (OS)Middle AgedPrognosisHepatitis CSustained virological responseLocal030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; Aged; Carcinoma Hepatocellular; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards ModelsLiver cancerHepatic decompensationmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIA03 medical and health scienceshepatocellularInternal medicinemedicineEarly Hepatocellular CarcinomaHumansRecurrencesHepatocellular carcinoma (HCC)Survival rateAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; HepatologyAgedProportional Hazards ModelsHepatologybusiness.industryHepatitis C Virus (HCV)CarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesNeoplasm RecurrenceAntiviral agentsLiver cirrhosisLiver functionNeoplasm Recurrence LocalbusinessSustained virological response (SVR)
researchProduct

Reply to: “Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients”

2014

Prof. Kitson’s comments give us the opportunity to clarify some issues that were not completely dealt with in our manuscript. In the study we reported a link between fructose intake and the severity of liver fibrosis in a cohort of Italian patients with genotype 1 chronic hepatitis C (CHC) [1], with an association found for industrial, but not for fruit fructose intake. Our results were in keeping with data already reported in patients with non-alcoholic fatty liver disease [2,3].

Liver CirrhosisMaleHepatologyFruitFRUCTOSE HCVLiver fibrosiHumansFemaleFructoseHepatitis C ChronicHepatitis C
researchProduct

Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply

2021

Liver CirrhosisMaleHepatologymedicine.drug_classbusiness.industryGastroenterologyProton-pump inhibitorProton Pump InhibitorsBone fracturemedicine.diseaseBioinformaticsFractures BonemedicineHumansPharmacology (medical)Point (geometry)businessAlimentary Pharmacology & Therapeutics
researchProduct

The abdominal wall hernia in cirrhotic patients: A historical challenge

2018

Abstract Background The incidence rate of abdominal wall hernia is 20–40% in cirrhotic patients. A surgical approach was originally performed only if complication signs and symptoms occurred. Several recent studies have demonstrated the usefulness of elective surgery. During recent decades, the indications for surgical timing have changed. Methods Cirrhotic patients with abdominal hernia who underwent surgical operation for abdominal wall hernia repair at the Policlinico “Paolo Giaccone” at Palermo University Hospital between January 2010 and September 2016 were identified in a prospective database, and the data collected were retrospectively reviewed; patients’ medical and surgical records…

Liver CirrhosisMaleHerniaAbdominal wall hernia; Cirrhosis; Emergency; Risk factors; Surgery; Surgery; Emergency Medicinemedicine.medical_treatmentAbdominal Hernia030230 surgerylaw.inventionAbdominal wallPostoperative Complications0302 clinical medicinelawAscitesMedicineProspective StudiesAged 80 and overlcsh:Medical emergencies. Critical care. Intensive care. First aidMiddle AgedHernia repairIntensive care unitTreatment Outcomemedicine.anatomical_structureCirrhosisElective Surgical ProceduresEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomResearch Articlemedicine.medical_specialtylcsh:SurgeryRisk Assessment03 medical and health sciencesHumansHerniaElective surgeryHerniorrhaphyAgedRetrospective StudiesCirrhosibusiness.industryAbdominal Walllcsh:RD1-811lcsh:RC86-88.9medicine.diseaseSurgeryRisk factorsEmergencyAbdominal wall herniaSurgeryRisk factorbusinessComplication
researchProduct

Coagulation and fibrosis in chronic liver disease.

2008

In the hepatic tissue repair mechanism, hepatic stellate cells (HSCs) are recruited at the site of injury and their changes reflect paracrine stimulation by all neighbouring cell types, including sinusoidal endothelial cells, Kupffer cells, hepatocytes, platelets and leucocytes. Thrombin converts circulating fibrinogen to fibrin, promotes platelet aggregation, is a potent activator of endothelial cells, acts as a chemoattractant for inflammatory cells and is a mitogen and chemoattractant for fibroblasts and vascular smooth muscle cells. Most of the cellular effects elicited by thrombin are mediated via a family of widely expressed G-protein-coupled receptors termed protease activated recept…

Liver CirrhosisMaleKupffer CellsReceptors Proteinase-ActivatedThrombin liver fibrosisProteinase-ActivatedChronic liver diseaseFibrinLiver diseaseThrombinFibrosisReceptorsHepatic Stellate CellsmedicineAnimalsHumansPlateletReceptorBlood CoagulationWound HealingAnimals; Anticoagulants; Blood Coagulation; Chronic Disease; Disease Progression; Endothelial Cells; Female; Hepatic Stellate Cells; Hepatocytes; Humans; Kupffer Cells; Liver Cirrhosis; Liver Diseases; Male; Rats; Receptors Proteinase-Activated; Receptors Thrombin; Thrombin; Wound Healing; Gastroenterologybiologybusiness.industryLiver DiseasesThrombinGastroenterologyAnticoagulantsEndothelial Cellsmedicine.diseaseRatsChronic DiseaseImmunologyDisease ProgressionHepatocytesbiology.proteinHepatic stellate cellCancer researchFemaleReceptors Thrombinbusinessmedicine.drug
researchProduct

Laparoscopic Microwave Thermal Ablation for the Treatment of Hepatocellular Carcinoma in Chronic Hepatic Patients

2020

Background: Laparoscopic microwave thermal ablation (LMWTA) is a well-established alternative treatment to liver resection for treatment of liver tumors. The aim of this study was to describe our experience in LMWTA for hepatocellular carcinoma (HCC) in chronic hepatic patients. Materials and Methods: A study group of 61 consecutive HCC patients treated with LMWTA from January, 2013 to May, 2020 were considered for this study. Patient characteristics, liver function test, operational characteristics, and complications were recorded. Results: Of the 61 patients who underwent LMWTA, median age was 64 (interquartile range [IQR]: 58-71) years, mean body mass index was 26.2 (IQR: 23.2-29.4); 44 …

Liver CirrhosisMaleLaparoscopic surgerymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentHepatitis C virusmedicine.disease_causeGastroenterologyLiver diseasePregnancymicrowave thermoablationInterquartile rangeInternal medicinemedicineHepatectomyHumansRisk factorMicrowavesAgedmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHyperthermia Inducedhepatocellular carcinomaHepatitis C ChronicMiddle Agedmedicine.diseaselaparoscopic surgerySurgeryHepatocellular carcinomaCatheter AblationFemaleLaparoscopySurgeryLiver function testsbusinessBody mass indexJournal of Laparoendoscopic & Advanced Surgical Techniques
researchProduct

Immune-inflammatory and metabolic effects of high dose furosemide plus hypertonic saline solution (HSS) treatment in cirrhotic subjects with refracto…

2016

Introduction Patients with chronic liver diseases are usually thin as a result of hypermetabolism and malnutrition expressed by reduced levels of leptin and impairment of other adyponectins such as visfatin. Aims We evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites. Methods 59 consecutive cirrhotic patients with refractory ascites unresponsive to outpatient treatment. Enrolled subjects were randomized to treatment with intravenous infusion of furosemide (125-250mg⁄bid) plus small volumes of HSS …

Liver CirrhosisMaleLeptinCirrhosisPhysiologyPeptide Hormonesmedicine.medical_treatmentdiureticlcsh:MedicineVisfatinPathology and Laboratory MedicineFurosemide; Hypertonic Saline Solution; TNF-alpha; IL-1beta; IL-6; ANP; BNP; Visfatin; Leptin; cirrhosis; refractory ascites; paracentesis; diureticBiochemistryGastroenterology0302 clinical medicineRecurrenceFurosemideImmune PhysiologyMedicine and Health SciencesParacentesisDiureticslcsh:ScienceImmune ResponseSalineHypertonicInnate Immune SystemMultidisciplinarymedicine.diagnostic_testLiver DiseasesPhysicsLeptinrefractory asciteAscitesClassical MechanicsFurosemideHematologyMiddle AgedBody FluidsBloodTreatment OutcomeCirrhosis030220 oncology & carcinogenesisPhysical SciencesHypermetabolismCytokinesAdministration IntravenousFemale030211 gastroenterology & hepatologyAnatomyInflammation MediatorsANPResearch ArticleTNF-alphamedicine.drugparacentesimedicine.medical_specialtyInflammatory DiseasesImmunologyGastroenterology and HepatologyBlood Plasma03 medical and health sciencesSigns and SymptomsDiagnostic MedicineOsmotic PressureInternal medicinePressuremedicineTonicityHumansAgedInflammationSaline Solution HypertonicIL-6business.industrylcsh:RBiology and Life SciencesMolecular DevelopmentIL-1betamedicine.diseaseHormonesHypertonic salineEndocrinologyImmune Systemlcsh:QHypertonic Saline SolutionDiureticbusinessBiomarkersDevelopmental BiologyBNPcirrhosi
researchProduct